Petros Pharmaceuticals (PTPI) Competitors $0.01 0.00 (-7.69%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. NERV, RLYB, RLMD, ABVC, LSB, ATHA, BGXX, FLGC, BCDA, and PRTGShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Minerva Neurosciences (NERV), Rallybio (RLYB), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Lakeshore Biopharma (LSB), Athira Pharma (ATHA), Bright Green (BGXX), Flora Growth (FLGC), BioCardia (BCDA), and Portage Biotech (PRTG). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Minerva Neurosciences Rallybio Relmada Therapeutics ABVC BioPharma Lakeshore Biopharma Athira Pharma Bright Green Flora Growth BioCardia Portage Biotech Petros Pharmaceuticals (NASDAQ:PTPI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership. Is PTPI or NERV more profitable? Minerva Neurosciences' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Minerva Neurosciences N/A N/A -6.74% Which has higher earnings and valuation, PTPI or NERV? Petros Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.13-$8.16M-$4.760.00Minerva NeurosciencesN/AN/A-$30M$0.198.79 Do institutionals and insiders hold more shares of PTPI or NERV? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor PTPI or NERV? Minerva Neurosciences received 346 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 55.79% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformPetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesMinerva NeurosciencesOutperform Votes34755.79% Underperform Votes27544.21% Which has more volatility & risk, PTPI or NERV? Petros Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Do analysts recommend PTPI or NERV? Minerva Neurosciences has a consensus target price of $5.00, indicating a potential upside of 199.40%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to PTPI or NERV? In the previous week, Petros Pharmaceuticals had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Petros Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.63 beat Petros Pharmaceuticals' score of -0.28 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Petros Pharmaceuticals Neutral Minerva Neurosciences Positive SummaryMinerva Neurosciences beats Petros Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$642,000.00$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio0.007.4522.4218.48Price / Sales0.13242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.006.516.774.25Net Income-$8.16M$143.21M$3.22B$248.23M7 Day PerformanceN/A3.97%3.26%3.29%1 Month PerformanceN/A0.37%0.02%2.42%1 Year PerformanceN/A2.60%18.01%5.54% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.3 of 5 stars$0.01-7.7%N/A-98.2%$642,000.00$5.11M0.0020Stock SplitShort Interest ↑Gap UpHigh Trading VolumeNERVMinerva Neurosciences3.638 of 5 stars$1.76flat$5.00+184.1%-29.2%$12.31MN/A-4.009RLYBRallybio2.3776 of 5 stars$0.29-4.0%$10.00+3,332.9%-83.3%$12.12M$636,000.00-0.1840Gap DownRLMDRelmada Therapeutics4.2714 of 5 stars$0.36-44.6%$4.25+1,090.1%-91.1%$11.85MN/A-0.1210Upcoming EarningsGap DownHigh Trading VolumeABVCABVC BioPharma1.0933 of 5 stars$1.00+2.4%N/A-15.2%$11.71M$509,589.00-1.1630Earnings ReportPositive NewsLSBLakeshore Biopharma1.3144 of 5 stars$1.24+1.6%N/AN/A$11.54M$672.27M0.00773Short Interest ↓ATHAAthira Pharma3.2127 of 5 stars$0.29+3.4%$13.83+4,605.2%-85.7%$11.48MN/A-0.1040Positive NewsGap UpBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownFLGCFlora Growth3.3222 of 5 stars$0.59+1.2%$5.00+751.8%-65.3%$11.41M$59.51M-0.44280Short Interest ↓Positive NewsBCDABioCardia3.7229 of 5 stars$2.42+22.8%$25.00+933.1%-45.9%$11.33M$58,000.00-0.5840Short Interest ↓Positive NewsTrading HaltedPRTGPortage Biotech0.7607 of 5 stars$10.77+27.5%N/A+143.7%$11.30MN/A-0.266Short Interest ↓Gap DownHigh Trading Volume Related Companies and Tools Related Companies Minerva Neurosciences Competitors Rallybio Competitors Relmada Therapeutics Competitors ABVC BioPharma Competitors Lakeshore Biopharma Competitors Athira Pharma Competitors Bright Green Competitors Flora Growth Competitors BioCardia Competitors Portage Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
